Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
4(100.0%)
4Total
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00615264Phase 3Completed

Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Role: lead

NCT01103284Phase 3Completed

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Role: lead

NCT01898286Phase 3Terminated

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

Role: lead

NCT00644501Phase 3Completed

Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes

Role: lead

All 4 trials loaded